Recombinant Biotinylated Cynomolgus LAG-3 / CD223 Protein, Mouse IgG2a Fc Tag, ultra sensitivity (primary amine labeling), 25 µg

Background
Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

Source
Recombinant Biotinylated Cynomolgus LAG-3, Mouse IgG2a Fc Tag, primary amine labeling (LA3-C8258) is expressed from human 293 cells (HEK293). It contains AA Ala 18 - His 449 (Accession # XP_005570011.1).
Predicted N-terminus: Ala 18

Molecular Characterization
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 73.5 kDa. The protein migrates as 80-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A specially optimized long-spacer biotin reagent (32.5 angstroms) is used in this product to minimize potential steric hindrance.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "LAG-3 : recent developments in combinational therapies in cancer"
Chavanton, Mialhe, Abrey et al
Cancer Sci (2024)
(2) "Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy"
Jeon, Hill, Moseman et al
J Immunother Cancer (2024) 12 (5)
(3) "Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial"
Schuler, Cuppens, Plönes et al
Nat Med (2024)
Showing 1-3 of 1612 papers.